Drug Database
LE

lercanidipine + valsartan (Levacalm / ZV Combi)

✓ Approved

LG Chem Ltd. · AGTR1 · Small Molecule

What is lercanidipine + valsartan?

lercanidipine + valsartan is a small molecule developed by LG Chem Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLevacalm, ZV Combi
CompanyLG Chem Ltd.
Drug ClassSmall Molecule
Molecular TargetAGTR1, CACNA1C
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, LG Chem Ltd.

Mechanism of Action

Molecular Targets

lercanidipine + valsartan acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

lercanidipine + valsartan is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedHealthcare quarterly (Toronto, Ont.)2026-08-30

Addressing Canada's Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation.

Mullie Thomas T, Chuck Anderson A

The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada's life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada's poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada's health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act.

PMID 42669639
Read full article →
PubMedRadiology case reports2026-08-30

Low-grade osteogenic tumor with secondary aneurysmal bone cyst: Distinguishing osteoblastoma from low-grade osteosarcoma in the setting of noncanonical molecular findings.

Shabbir-Hussain Roban R, Malerba Romina R, Aljohani Reem R, Nani Julius J et al.

Low-grade osteogenic tumors in the appendicular skeleton can show overlapping radiologic and histologic features, especially when secondary aneurysmal bone cyst (ABC) change is present. Osteoblastoma (OB) with secondary ABC and low-grade osteosarcoma (LG-OS) with secondary ABC may be difficult to distinguish, and noncanonical molecular alterations such as KMT2D or ZRSR2 variants may further complicate interpretation. We present an 18-year-old male presented with 6 months of atraumatic hip/knee pain and progressive difficulty weight-bearing. Imaging demonstrated a proximal femoral intramedullary lesion with cortical thickening, impending breakthrough, and surrounding marrow/soft-tissue edema. The differential diagnosis included OB vs LG-OS. Two image-guided biopsies favored OB. The patient underwent wide resection with allograft prosthetic composite reconstruction; margins were negative, and overall pathology supported OB with secondary ABC. Recovery was uncomplicated aside from transient urinary retention. By postoperative week 8, the patient had progressed to full weight-bearing with minimal pain. CT chest demonstrated stable benign nodules under surveillance. The integrated radiologic, histologic, immunophenotypic, and molecular profile supports a low-grade osteogenic tumor with secondary ABC.

PMID 42668586
Read full article →
PubMedBiochemistry. Biokhimiia2026-08-30

Age-Related Changes in bis-Retinoids of Lipofuscin Granules in Human Retinal Pigment Epithelium Cells.

Yakovleva Marina A MA, Kostyukov Alexey A AA, Aronshtam Natalya L NL, Shilkrot Patimat M PM et al.

Lipofuscin granules (LGs) in retinal pigment epithelium (RPE) cells contain bis-retinoids and their oxidation and degradation products, rendering them photo- and cytotoxic to intracellular structures. LGs are implicated in the pathogenesis of multiple visual pathologies, including age-related macular degeneration (AMD). They exhibit strong autofluorescence, which has led to the development of fundus autofluorescence (FAF) imaging as a non-invasive diagnostic method in ophthalmology. Spectral analysis of autofluorescence can expand the capabilities of this method, including for preclinical diagnostics, as pathological conditions are often associated with increased proportions of oxidized bis-retinoid derivatives that alter LG autofluorescence parameters. However, limited knowledge of age-dependent changes in LG bis-retinoid composition remains a key limitation. In this study, we combined fluorescence spectroscopy, confocal fluorescence microscopy, and fluorescence lifetime imaging (time-correlated single-photon counting) to demonstrate that, under physiological conditions, aging is accompanied by a progressive increase in the relative abundance of oxidation and degradation products of bis-retinoids in LGs. These findings provide an age-dependent baseline for distinguishing physiological and pathological states, thereby improving the potential of FAF imaging for early (preclinical) diagnosis.

PMID 42669560
Read full article →
PubMedEuropean journal of heart failure2026-08-30

Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials.

Lu Henri H, Claggett Brian L BL, Ostrominski John W JW, Pfeffer Marc A MA et al.

Blood pressure (BP) control is a Class I recommendation for the management of heart failure with preserved ejection fraction (HFpEF); however, evidence supporting systolic BP (SBP) targets remains limited. We investigated associations between BP control and subsequent outcomes in patients with HF with mildly reduced EF (HFmrEF)/HFpEF. We pooled TOPCAT (Americas), PARAGON-HF, DELIVER, and FINEARTS-HF, which tested spironolactone, sacubitril/valsartan, dapagliflozin, and finerenone, respectively, versus placebo or active control in patients with HF and an LVEF >40% (DELIVER), ≥40% (FINEARTS-HF), or ≥45% (TOPCAT-Americas, PARAGON-HF). Daily BPs were estimated by interpolation from standardized office measurements obtained at randomization and prespecified visits. Time in target range (TIR) was the percentage of the first year after randomization during which SBP was 110-<130 mmHg. Continuous associations between TIR and subsequent risk of HF hospitalization or cardiovascular death, its individual components, and all-cause death was assessed using landmark Cox proportional hazards models with linear splines, adjusted for baseline cardiovascular risk factors. Among 17,788 patients (mean age 72±9 years; 47% women; mean baseline SBP 129±15 mmHg), the median TIR was 38% (≈139 days). Randomization to active therapies increased TIR by 2% (95% CI: -2 to 6) with spironolactone, 7% (5 to 9) with sacubitril/valsartan, 2% (0 to 4) with dapagliflozin, and 3% (1 to 5) with finerenone. Higher TIR was associated with lower subsequent risk of the composite outcome (P=0.021), primarily driven by lower HF hospitalization risk (P=0.007); associations with cardiovascular death and all-cause death were not significant. Sensitivity analyses using stricter (120-<130 mmHg) or more liberal ranges (100-<130 and 120-<140 mmHg) yielded qualitatively similar findings. In patients with HFmrEF/HFpEF, BP control during the first year was associated with a lower subsequent risk of HF hospitalization. ClinicalTrials.gov ID NCT00094302 (TOPCAT), NCT01920711 (PARAGON-HF), NCT03619213 (DELIVER), NCT04435626 (FINEARTS-HF).

PMID 42669134
Read full article →
PubMedBiodiversity data journal2026-08-30

A Darwin Core dataset of scorpions (Arachnida, Scorpiones) from the Royal Belgian Institute of Natural Sciences (RBINS) Collections.

Durante Fabiola F, Prendini Lorenzo L, Pizzolotto Roberto R, Wérenne Gladys G et al.

This data paper details the publication of a dataset derived from the scorpion (Order Scorpiones C.L. Koch, 1850) collections preserved at the Royal Belgian Institute of Natural Sciences (RBINS), Brussels. The dataset includes all 3,652 specimens mostly identified to genus or species level during a recent re-evaluation. To maximise accessibility and interoperability, the entire dataset was fully standardised using the Darwin Core (DwC) standard and published as open data. The published dataset comprises a significant collection of records, encompassing eleven families, 56 genera and 117 species of scorpions. Geographically, the specimens originate from a wide range of locations, in 59 countries. The records within this dataset span a substantial chronological period, with collection dates ranging from 1872 to 2023. Most of the specimens were collected during expeditions led by researchers of RBINS. The mobilisation and standardisation of this rich historical collection provide a valuable resource for global biodiversity informatics, supporting crucial research in taxonomy, ecology and biogeography of the order Scorpiones.

PMID 42668906
Read full article →
PubMedPhysical chemistry chemical physics : PCCP2026-08-30

Ballistic performance limits of sub-5-nm monolayer GeS2 and SnS2 MOSFETs from first-principles quantum transport.

Ma Xing-Yu XY, Guo Yan-Dong YD, Jiang Yue Y, Duan Xiao-Lu XL et al.

Two-dimensional chalcogenide semiconductors provide an attractive platform for deeply scaled transistors because their atomically thin bodies enable strong electrostatic control and effective suppression of short-channel effects. Here, we systematically investigate the ballistic transport limits of monolayer GeS2 and SnS2 double-gated metal-oxide-semiconductor field-effect transistors (MOSFETs) using density functional theory combined with the nonequilibrium Green-function formalism. Both n- and p-type devices are evaluated at gate lengths of 5, 3, and 1 nm under the 2028 International Technology Roadmap for Semiconductors high-performance (HP) and low-power (LP) requirements. By optimizing the source/drain doping concentration and underlap length, the n-type armchair GeS2 and SnS2 MOSFETs with Lg = 5 nm deliver ultrahigh on-state currents of 5064 and 4557 µA µm-1 for HP applications, and 1072 and 2042 µA µm-1 for LP applications, respectively. Moreover, the intrinsic delay time and power-delay product remain well below the corresponding ITRS limits. Further analysis reveals that the excellent current-driving capability originates from the favorable balance between carrier velocity and density of states associated with the transport-direction effective mass. These findings suggest the potential of monolayer GeS2 and SnS2 as promising channel candidates for extending two-dimensional electronics toward the deeply scaled, energy-efficient post-silicon technology node.

PMID 42669410
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lercanidipine + valsartan